Witty and Dekkers bemoan austerity measures, but remain tight lipped on way forward
This article was originally published in Scrip
GSK CEO, Andrew Witty, this week complained that European governments treated the purchase of life saving drugs like any other procurement exercise, while Dr Marjin Dekkers, chairman of Bayer’s management board, pointed to their failure to value innovation. However, neither company would comment on potential alternatives or action plans for cash strapped policy makers.
You may also be interested in...
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.